Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 265 Leukemia 183 Carcinoma, Non-Small-Cell Lung 168 Lymphoma 159 Lung Neoplasms 148 Prostatic Neoplasms 134 Precursor Cell Lymphoblastic Leukemia-Lymphoma 130 Ovarian Neoplasms 117 Colorectal Neoplasms 115 Sarcoma 108 Central Nervous System Neoplasms 107 Head and Neck Neoplasms 98 Leukemia, Myeloid, Acute 95 Multiple Myeloma 93 Squamous Cell Carcinoma of Head and Neck 83 Rectal Neoplasms 77 Colonic Neoplasms 71 Uterine Cervical Neoplasms 65 Neoplasm Metastasis 65 Neuroblastoma 64 Carcinoma, Ovarian Epithelial 64 Brain Neoplasms 64 Neoplasms 63 Fallopian Tube Neoplasms 62 Lymphoma, Large B-Cell, Diffuse 61 Astrocytoma 59 Melanoma 58 Leukemia, Lymphocytic, Chronic, B-Cell 56 Burkitt Lymphoma 56 Hodgkin Disease 55

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Breast Cancer Invasive Nos × Clear all

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡